Geron Corporation (GERN)
USD 1.36
(-7.82%)
USD 1.36
(-7.82%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 394.07 Million USD | 106.78% |
| 2022 | 190.57 Million USD | -15.69% |
| 2021 | 226.03 Million USD | -16.51% |
| 2020 | 270.72 Million USD | 63.57% |
| 2019 | 165.51 Million USD | -10.67% |
| 2018 | 185.28 Million USD | 67.96% |
| 2017 | 110.31 Million USD | -15.31% |
| 2016 | 130.24 Million USD | -12.44% |
| 2015 | 148.76 Million USD | -13.77% |
| 2014 | 172.51 Million USD | 156.16% |
| 2013 | 67.34 Million USD | -32.52% |
| 2012 | 99.8 Million USD | -37.64% |
| 2011 | 160.04 Million USD | -31.48% |
| 2010 | 233.58 Million USD | 29.49% |
| 2009 | 180.38 Million USD | 2.36% |
| 2008 | 176.21 Million USD | -19.5% |
| 2007 | 218.89 Million USD | -0.86% |
| 2006 | 220.8 Million USD | 9.72% |
| 2005 | 201.24 Million USD | 52.6% |
| 2004 | 131.87 Million USD | 11.65% |
| 2003 | 118.11 Million USD | 94.69% |
| 2002 | 60.66 Million USD | -36.95% |
| 2001 | 96.23 Million USD | -15.61% |
| 2000 | 114.03 Million USD | 79.01% |
| 1999 | 63.7 Million USD | 43.15% |
| 1998 | 44.5 Million USD | 70.5% |
| 1997 | 26.1 Million USD | -9.38% |
| 1996 | 28.8 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 482.07 Million USD | 22.33% |
| 2024 Q2 | 449.39 Million USD | -6.78% |
| 2023 Q3 | 413.01 Million USD | -0.55% |
| 2023 Q2 | 415.29 Million USD | -2.26% |
| 2023 FY | 394.07 Million USD | 106.78% |
| 2023 Q1 | 424.87 Million USD | 122.94% |
| 2023 Q4 | 394.07 Million USD | -4.59% |
| 2022 Q3 | 232.6 Million USD | -2.33% |
| 2022 Q1 | 198.42 Million USD | -12.22% |
| 2022 Q2 | 238.16 Million USD | 20.03% |
| 2022 FY | 190.57 Million USD | -15.69% |
| 2022 Q4 | 190.57 Million USD | -18.07% |
| 2021 Q3 | 229.09 Million USD | -9.15% |
| 2021 Q1 | 258.6 Million USD | -4.48% |
| 2021 FY | 226.03 Million USD | -16.51% |
| 2021 Q4 | 226.03 Million USD | -1.34% |
| 2021 Q2 | 252.17 Million USD | -2.49% |
| 2020 FY | 270.72 Million USD | 63.57% |
| 2020 Q1 | 142.88 Million USD | -13.67% |
| 2020 Q2 | 274.81 Million USD | 92.33% |
| 2020 Q3 | 285.79 Million USD | 4.0% |
| 2020 Q4 | 270.72 Million USD | -5.27% |
| 2019 Q2 | 166.22 Million USD | -5.37% |
| 2019 Q3 | 164.25 Million USD | -1.19% |
| 2019 Q4 | 165.51 Million USD | 0.77% |
| 2019 FY | 165.51 Million USD | -10.67% |
| 2019 Q1 | 175.66 Million USD | -5.19% |
| 2018 Q2 | 183.26 Million USD | 73.69% |
| 2018 FY | 185.28 Million USD | 67.96% |
| 2018 Q1 | 105.51 Million USD | -4.35% |
| 2018 Q4 | 185.28 Million USD | -1.41% |
| 2018 Q3 | 187.93 Million USD | 2.55% |
| 2017 Q2 | 124.28 Million USD | -3.54% |
| 2017 Q1 | 128.84 Million USD | -1.08% |
| 2017 FY | 110.31 Million USD | -15.31% |
| 2017 Q4 | 110.31 Million USD | -3.44% |
| 2017 Q3 | 114.24 Million USD | -8.08% |
| 2016 Q4 | 130.24 Million USD | -4.39% |
| 2016 Q1 | 143.14 Million USD | -3.78% |
| 2016 Q2 | 137.41 Million USD | -4.0% |
| 2016 Q3 | 136.23 Million USD | -0.86% |
| 2016 FY | 130.24 Million USD | -12.44% |
| 2015 FY | 148.76 Million USD | -13.77% |
| 2015 Q4 | 148.76 Million USD | -3.41% |
| 2015 Q1 | 165.8 Million USD | -3.89% |
| 2015 Q2 | 159.08 Million USD | -4.06% |
| 2015 Q3 | 154.01 Million USD | -3.18% |
| 2014 Q4 | 172.51 Million USD | 19.59% |
| 2014 FY | 172.51 Million USD | 156.16% |
| 2014 Q2 | 149.33 Million USD | -3.91% |
| 2014 Q3 | 144.24 Million USD | -3.41% |
| 2014 Q1 | 155.4 Million USD | 130.77% |
| 2013 FY | 67.34 Million USD | -32.52% |
| 2013 Q2 | 73.41 Million USD | -11.4% |
| 2013 Q3 | 68.71 Million USD | -6.4% |
| 2013 Q4 | 67.34 Million USD | -1.99% |
| 2013 Q1 | 82.85 Million USD | -16.98% |
| 2012 FY | 99.8 Million USD | -37.64% |
| 2012 Q4 | 99.8 Million USD | -10.11% |
| 2012 Q3 | 111.02 Million USD | -12.02% |
| 2012 Q1 | 141.18 Million USD | -11.78% |
| 2012 Q2 | 126.19 Million USD | -10.62% |
| 2011 Q4 | 160.04 Million USD | -15.05% |
| 2011 FY | 160.04 Million USD | -31.48% |
| 2011 Q3 | 188.4 Million USD | -5.95% |
| 2011 Q2 | 200.33 Million USD | -7.69% |
| 2011 Q1 | 217.02 Million USD | -7.09% |
| 2010 FY | 233.58 Million USD | 29.49% |
| 2010 Q4 | 233.58 Million USD | 43.93% |
| 2010 Q3 | 162.29 Million USD | -5.17% |
| 2010 Q2 | 171.13 Million USD | -5.31% |
| 2010 Q1 | 180.72 Million USD | 0.19% |
| 2009 Q4 | 180.38 Million USD | -6.5% |
| 2009 Q1 | 211.53 Million USD | 20.04% |
| 2009 FY | 180.38 Million USD | 2.36% |
| 2009 Q2 | 199.97 Million USD | -5.46% |
| 2009 Q3 | 192.92 Million USD | -3.53% |
| 2008 Q3 | 187.85 Million USD | -6.36% |
| 2008 FY | 176.21 Million USD | -19.5% |
| 2008 Q2 | 200.6 Million USD | -4.75% |
| 2008 Q1 | 210.61 Million USD | -3.78% |
| 2008 Q4 | 176.21 Million USD | -6.2% |
| 2007 FY | 218.89 Million USD | -0.86% |
| 2007 Q2 | 228.23 Million USD | -0.33% |
| 2007 Q3 | 217.6 Million USD | -4.66% |
| 2007 Q4 | 218.89 Million USD | 0.59% |
| 2007 Q1 | 228.98 Million USD | 3.71% |
| 2006 Q2 | 190.58 Million USD | -1.92% |
| 2006 Q4 | 220.8 Million USD | 21.29% |
| 2006 Q3 | 182.04 Million USD | -4.48% |
| 2006 Q1 | 194.31 Million USD | -3.44% |
| 2006 FY | 220.8 Million USD | 9.72% |
| 2005 FY | 201.24 Million USD | 52.6% |
| 2005 Q4 | 201.24 Million USD | -4.06% |
| 2005 Q3 | 209.75 Million USD | 52.06% |
| 2005 Q2 | 137.93 Million USD | 1.52% |
| 2005 Q1 | 135.87 Million USD | 3.03% |
| 2004 Q2 | 108.96 Million USD | -4.98% |
| 2004 FY | 131.87 Million USD | 11.65% |
| 2004 Q3 | 99.63 Million USD | -8.56% |
| 2004 Q1 | 114.67 Million USD | -2.91% |
| 2004 Q4 | 131.87 Million USD | 32.35% |
| 2003 Q2 | 63.66 Million USD | 21.23% |
| 2003 Q4 | 118.11 Million USD | 100.23% |
| 2003 FY | 118.11 Million USD | 94.69% |
| 2003 Q3 | 58.98 Million USD | -7.34% |
| 2003 Q1 | 52.51 Million USD | -13.45% |
| 2002 Q2 | 76.26 Million USD | -9.67% |
| 2002 Q3 | 68.51 Million USD | -10.17% |
| 2002 Q1 | 84.43 Million USD | -12.26% |
| 2002 Q4 | 60.66 Million USD | -11.45% |
| 2002 FY | 60.66 Million USD | -36.95% |
| 2001 FY | 96.23 Million USD | -15.61% |
| 2001 Q2 | 103.27 Million USD | -4.16% |
| 2001 Q1 | 107.76 Million USD | -5.49% |
| 2001 Q3 | 96.81 Million USD | -6.26% |
| 2001 Q4 | 96.23 Million USD | -0.61% |
| 2000 Q3 | 115.2 Million USD | -3.46% |
| 2000 FY | 114.03 Million USD | 79.01% |
| 2000 Q4 | 114.03 Million USD | -1.02% |
| 2000 Q1 | 98.5 Million USD | 54.64% |
| 2000 Q2 | 119.33 Million USD | 21.14% |
| 1999 Q1 | 42.3 Million USD | -4.94% |
| 1999 Q3 | 68.2 Million USD | 9.65% |
| 1999 Q4 | 63.7 Million USD | -6.6% |
| 1999 FY | 63.7 Million USD | 43.15% |
| 1999 Q2 | 62.2 Million USD | 47.04% |
| 1998 Q1 | 41.9 Million USD | 60.54% |
| 1998 FY | 44.5 Million USD | 70.5% |
| 1998 Q4 | 44.5 Million USD | 16.8% |
| 1998 Q3 | 38.1 Million USD | -6.39% |
| 1998 Q2 | 40.7 Million USD | -2.86% |
| 1997 Q4 | 26.1 Million USD | -7.77% |
| 1997 Q1 | 25.8 Million USD | -10.42% |
| 1997 Q3 | 28.3 Million USD | -8.71% |
| 1997 FY | 26.1 Million USD | -9.38% |
| 1997 Q2 | 31 Million USD | 20.16% |
| 1996 Q1 | 18.1 Million USD | 0.0% |
| 1996 Q4 | 28.8 Million USD | -10.0% |
| 1996 FY | 28.8 Million USD | 0.0% |
| 1996 Q2 | 18.7 Million USD | 3.31% |
| 1996 Q3 | 32 Million USD | 71.12% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 73.518% |
| Alkermes plc | 2.13 Billion USD | 81.553% |
| Agenus Inc. | 313.91 Million USD | -25.537% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 89.71% |
| Aptorum Group Limited | 20.64 Million USD | -1809.275% |
| Ardelyx, Inc. | 297.57 Million USD | -32.427% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 48.524% |
| Bicycle Therapeutics plc | 595.34 Million USD | 33.807% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -434.688% |
| ChromaDex Corporation | 54.96 Million USD | -616.971% |
| Chimerix, Inc. | 212.77 Million USD | -85.209% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1293.854% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 10.634% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 82.325% |
| Precision BioSciences, Inc. | 159.78 Million USD | -146.635% |
| Dyadic International, Inc. | 8.21 Million USD | -4694.558% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1141.575% |
| Fortress Biotech, Inc. | 167.52 Million USD | -135.233% |
| Lantern Pharma Inc. | 43.64 Million USD | -802.858% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -144.256% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -2616.52% |
| Incyte Corporation | 6.78 Billion USD | 94.189% |
| IO Biotech, Inc. | 150.71 Million USD | -161.466% |
| Jaguar Health, Inc. | 50.76 Million USD | -676.306% |
| Novavax, Inc. | 1.85 Billion USD | 78.76% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -3.593% |
| Opthea Limited | 188.79 Million USD | -108.736% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 52.696% |
| ContextLogic Inc. | 423 Million USD | 6.838% |
| MiMedx Group, Inc. | 239.04 Million USD | -64.853% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -126.838% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -7522.801% |
| NextCure, Inc. | 129.41 Million USD | -204.499% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -630.474% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -972.929% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1120.012% |
| Vaxcyte, Inc. | 1.4 Billion USD | 72.01% |
| PDS Biotechnology Corporation | 59.39 Million USD | -563.538% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 38.478% |
| Pharming Group N.V. | 462.85 Million USD | 14.86% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -918.811% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 37.304% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1982.45% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1982.45% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -138.372% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -770.175% |
| Acelyrin, Inc. | 742.69 Million USD | 46.939% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -5883.066% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -6054.553% |
| Summit Therapeutics Inc. | 202.94 Million USD | -94.175% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -429.857% |
| Senti Biosciences, Inc. | 119.48 Million USD | -229.815% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -72.581% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -134.326% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -4669.164% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -8155.03% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 16.01% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -218.695% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -43.327% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 16.658% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -3799.812% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -83.713% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -34707.478% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 4.776% |
| Immix Biopharma, Inc. | 19.92 Million USD | -1877.781% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -6.5% |
| MEI Pharma, Inc. | 41.37 Million USD | -852.45% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1116.059% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -15.633% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -236.171% |
| Fortress Biotech, Inc. | 167.52 Million USD | -135.233% |
| Precigen, Inc. | 151.04 Million USD | -160.903% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1058.434% |
| AlloVir, Inc. | 190.79 Million USD | -106.543% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -4.682% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 22.153% |
| ImmuCell Corporation | 43.8 Million USD | -799.55% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 39.309% |
| Onconetix, Inc. | 88.82 Million USD | -343.672% |
| PureTech Health plc | 693.97 Million USD | 43.215% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -303.415% |
| Elevation Oncology, Inc. | 89.09 Million USD | -342.33% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -6254.015% |
| Seer, Inc. | 436.26 Million USD | 9.671% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -382.954% |
| Innoviva, Inc. | 1.24 Billion USD | 68.309% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -197.589% |
| ESSA Pharma Inc. | 149.12 Million USD | -164.264% |
| GlycoMimetics, Inc. | 45.31 Million USD | -769.609% |
| GT Biopharma, Inc. | 14.1 Million USD | -2693.082% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -27.991% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -63.041% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 16.493% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -677.316% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -313.893% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -62294.472% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 30.417% |
| Aptose Biosciences Inc. | 12.92 Million USD | -2949.523% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -1681.998% |
| Soligenix, Inc. | 9.79 Million USD | -3922.281% |
| Century Therapeutics, Inc. | 360.69 Million USD | -9.256% |
| Kura Oncology, Inc. | 448.93 Million USD | 12.22% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -44.802% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -2178.554% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -255.307% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -92.091% |
| Autolus Therapeutics plc | 375.38 Million USD | -4.98% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -56.606% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -10.95% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -702.076% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 40.394% |
| GRI Bio, Inc. | 2.95 Million USD | -13231.394% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -3615.866% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -131.109% |
| IGM Biosciences, Inc. | 423.41 Million USD | 6.928% |
| INmune Bio, Inc. | 57 Million USD | -591.349% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -77.108% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -369.466% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1408.895% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -5625.19% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -423.856% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -167.609% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -138.107% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 37.409% |
| Verastem, Inc. | 149.71 Million USD | -163.212% |
| Abeona Therapeutics Inc. | 64 Million USD | -515.725% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 23.055% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -155.136% |
| Histogen Inc. | 19.07 Million USD | -1966.146% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -1639.837% |
| Surrozen, Inc. | 46.08 Million USD | -755.2% |
| Organovo Holdings, Inc. | 6.34 Million USD | -6106.899% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -9046.223% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -173.613% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -3239.061% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -423.564% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -4525.712% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -8.57% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -2077.89% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 8.227% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -3024.681% |
| Apollomics, Inc. | 55.38 Million USD | -611.495% |
| Amarin Corporation plc | 831.68 Million USD | 52.617% |
| Mesoblast Limited | 669.15 Million USD | 41.108% |
| Turnstone Biologics Corp. | 112.81 Million USD | -249.312% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 31.555% |
| Synaptogenix, Inc. | 31.11 Million USD | -1166.569% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -3134.373% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 28.096% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -6610.805% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -5265.112% |
| Exelixis, Inc. | 2.94 Billion USD | 86.607% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1617.631% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -8.103% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 50.037% |
| NLS Pharmaceutics AG | 1.84 Million USD | -21240.152% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -4839.141% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -2581.701% |
| Gritstone bio, Inc. | 177.76 Million USD | -121.679% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -313.164% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -2106.192% |
| Avid Bioservices, Inc. | 336.55 Million USD | -17.09% |
| Insmed Incorporated | 1.32 Billion USD | 70.367% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -3992.874% |
| MediWound Ltd. | 66.45 Million USD | -492.961% |
| OmniAb, Inc. | 401.98 Million USD | 1.967% |
| Alector, Inc. | 621.82 Million USD | 36.626% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -9.893% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -7227.557% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -595.117% |
| Zai Lab Limited | 1.03 Billion USD | 61.973% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 17.636% |
| Aura Biosciences, Inc. | 255.07 Million USD | -54.494% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 47.459% |
| Immunic, Inc. | 54.29 Million USD | -625.752% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -48.024% |
| Veracyte, Inc. | 1.13 Billion USD | 65.366% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -3233.192% |
| FibroGen, Inc. | 423.52 Million USD | 6.954% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -11117.649% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -8219.799% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -7158.083% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 96.541% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -4375.593% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 23.843% |
| TG Therapeutics, Inc. | 329.58 Million USD | -19.567% |
| Galecto, Inc. | 38.22 Million USD | -930.884% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1274.236% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 90.956% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -67.404% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1486.33% |
| XBiotech Inc. | 227.24 Million USD | -73.416% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -313.164% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -176.351% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -37.829% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -208.187% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -3.162% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 73.57% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -8.013% |
| Vaxxinity, Inc. | 44.35 Million USD | -788.499% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 23.771% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -2017.626% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -29.184% |
| NexImmune, Inc. | 8.59 Million USD | -4485.505% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -3577.732% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -2200.852% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.809% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -1679.033% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -100361.678% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -127.357% |
| Ainos, Inc. | 31.84 Million USD | -1137.606% |
| Pluri Inc. | 39.52 Million USD | -896.979% |
| Prothena Corporation plc | 696.38 Million USD | 43.411% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -39.439% |
| Celularity Inc. | 143.88 Million USD | -173.875% |
| Rallybio Corporation | 115.62 Million USD | -240.837% |
| Cue Biopharma, Inc. | 61.53 Million USD | -540.462% |
| MeiraGTx Holdings plc | 458.16 Million USD | 13.989% |
| Omeros Corporation | 378.26 Million USD | -4.179% |
| Humacyte, Inc. | 128.22 Million USD | -207.336% |
| Immunocore Holdings plc | 597 Million USD | 33.991% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1160.68% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -475.042% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 62.442% |
| CalciMedica, Inc. | 12.18 Million USD | -3134.108% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -55.362% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -130.578% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -26.698% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 30.289% |
| Pulmatrix, Inc. | 33.95 Million USD | -1060.481% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1351.691% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -179.768% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 69.709% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -202.695% |
| Cytokinetics, Incorporated | 824.31 Million USD | 52.194% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -1765.625% |
| Nutriband Inc. | 7.51 Million USD | -5142.356% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -399.121% |
| Vor Biopharma Inc. | 209.82 Million USD | -87.809% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 94.544% |
| Evogene Ltd. | 51.1 Million USD | -671.171% |
| ProKidney Corp. | 420.55 Million USD | 6.296% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -618.684% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -4039.333% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 27.875% |
| CorMedix Inc. | 82.05 Million USD | -380.229% |
| BioLineRx Ltd. | 63.92 Million USD | -516.466% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 2.109% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1297.433% |
| Atai Life Sciences N.V. | 293.47 Million USD | -34.278% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -141.573% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -209.278% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 29.883% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -307.444% |
| MediciNova, Inc. | 66.26 Million USD | -494.652% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -348.078% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -8731.102% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4145.036% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 33.007% |
| Biomea Fusion, Inc. | 199.92 Million USD | -97.11% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 79.294% |
| Mereo BioPharma Group plc | 66.49 Million USD | -492.604% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 18.763% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 35.701% |
| Absci Corporation | 234.48 Million USD | -68.064% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -5287.232% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -15.942% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -138.715% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 25.126% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -41.911% |
| Allakos Inc. | 243.61 Million USD | -61.765% |
| Imunon, Inc. | 21.91 Million USD | -1697.95% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -52.924% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 36.594% |
| BioAtla, Inc. | 119.65 Million USD | -229.335% |
| NLS Pharmaceutics AG | 1.84 Million USD | -21240.152% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -12138.385% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 38.697% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -310.774% |
| XOMA Corporation | 234.3 Million USD | -68.192% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -78.126% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -213.146% |
| aTyr Pharma, Inc. | 122.06 Million USD | -222.836% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -156.055% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 32.088% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 19.646% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -256.73% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -2499.865% |
| Akari Therapeutics, Plc | 4.35 Million USD | -8948.817% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2213.015% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 77.264% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -12678.138% |
| UroGen Pharma Ltd. | 178.31 Million USD | -121.005% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 16.285% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -70813.328% |
| Orgenesis Inc. | 14.55 Million USD | -2608.054% |
| Entera Bio Ltd. | 11.76 Million USD | -3249.562% |
| GH Research PLC | 226.3 Million USD | -74.139% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -620.51% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -266.801% |
| Xencor, Inc. | 952.69 Million USD | 58.636% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -4962.79% |
| Replimune Group, Inc. | 487.72 Million USD | 19.201% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -4782.563% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 39.227% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -12678.138% |
| Portage Biotech Inc. | 7.77 Million USD | -4965.895% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -8731.102% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -42.294% |
| OncoCyte Corporation | 74.89 Million USD | -426.192% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -19281.6% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -6710.097% |
| Purple Biotech Ltd. | 44.3 Million USD | -789.522% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1054.768% |
| scPharmaceuticals Inc. | 94.47 Million USD | -317.104% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -2083.857% |
| HilleVax, Inc. | 344.43 Million USD | -14.413% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -12307.935% |
| Tharimmune, Inc. | 10.94 Million USD | -3500.053% |
| Genprex, Inc. | 10.67 Million USD | -3593.103% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 20.58% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -309.421% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -16143.858% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -9360.607% |
| OKYO Pharma Limited | 1.54 Million USD | -25468.365% |
| Savara Inc. | 177.56 Million USD | -121.935% |
| Curis, Inc. | 77.28 Million USD | -409.92% |
| Daré Bioscience, Inc. | 21.28 Million USD | -1751.668% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -516.237% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -4773.559% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -1934.361% |
| BeiGene, Ltd. | 5.8 Billion USD | 93.212% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -3138.36% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 81.132% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -10.092% |
| Erasca, Inc. | 395.29 Million USD | 0.309% |
| bluebird bio, Inc. | 619.16 Million USD | 36.353% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -9015.021% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 94.24% |
| DBV Technologies S.A. | 182.98 Million USD | -115.359% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -9015.021% |
| Moderna, Inc. | 18.42 Billion USD | 97.861% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -2063.232% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -3301.312% |
| Molecular Templates, Inc. | 35.38 Million USD | -1013.744% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -185.015% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 50.048% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -29.735% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -279.116% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 15.367% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -25.727% |
| MacroGenics, Inc. | 306.82 Million USD | -28.439% |
| RenovoRx, Inc. | 1.46 Million USD | -26781.037% |
| Adicet Bio, Inc. | 207.29 Million USD | -90.104% |
| Prime Medicine, Inc. | 193.85 Million USD | -103.288% |
| Aditxt, Inc. | 44.57 Million USD | -784.008% |
| Adagene Inc. | 115.72 Million USD | -240.517% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -8747.312% |
| Quantum-Si incorporated | 298.25 Million USD | -32.129% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 73.507% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -5011.814% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -12.183% |
| SciSparc Ltd. | 11.18 Million USD | -3424.2% |
| Vericel Corporation | 353.65 Million USD | -11.429% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3126.796% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -592.569% |
| Generation Bio Co. | 374.75 Million USD | -5.155% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -54.742% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -148.523% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -15.441% |
| Invivyd, Inc. | 229.18 Million USD | -71.95% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 53.307% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -3138.28% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -116.062% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -1829.475% |
| 2seventy bio, Inc. | 565.42 Million USD | 30.305% |
| ADMA Biologics, Inc. | 329.18 Million USD | -19.714% |
| Clene Inc. | 52.34 Million USD | -652.901% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -570.947% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -203.383% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4145.036% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 39.716% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -280.341% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -202.238% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -303.965% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -455.06% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -62.47% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 79.895% |
| Evaxion Biotech A/S | 12.88 Million USD | -2957.55% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -56.342% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 47.644% |
| Trevena, Inc. | 40.6 Million USD | -870.511% |
| Surrozen, Inc. | 46.08 Million USD | -755.2% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -74.48% |
| Cingulate Inc. | 3.49 Million USD | -11186.932% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -2269.812% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -499.903% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -3272.602% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -46.76% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 47.383% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -213.027% |
| Clearmind Medicine Inc. | 4.32 Million USD | -9012.871% |
| Kronos Bio, Inc. | 213.27 Million USD | -84.77% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -146.63% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -4503.364% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -6.943% |
| Statera Biopharma, Inc. | 21.16 Million USD | -1761.511% |
| ImmunityBio, Inc. | 504.45 Million USD | 21.88% |
| Korro Bio, Inc. | 221.66 Million USD | -77.782% |
| Kineta, Inc. | 10.28 Million USD | -3733.051% |
| BioVie Inc. | 25.2 Million USD | -1463.276% |
| Codexis, Inc. | 136.56 Million USD | -188.571% |
| Celularity Inc. | 143.88 Million USD | -173.875% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 37.975% |
| Celcuity Inc. | 191.21 Million USD | -106.086% |
| Virax Biolabs Group Limited | 5.48 Million USD | -7085.963% |
| Cibus, Inc. | 544.41 Million USD | 27.614% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -213.022% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -1818.205% |
| IN8bio, Inc. | 33.7 Million USD | -1069.053% |
| Kodiak Sciences Inc. | 479.37 Million USD | 17.793% |
| Annexon, Inc. | 297.67 Million USD | -32.385% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -127.776% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -186.665% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -1777.178% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 86.821% |
| Eyenovia, Inc. | 28.77 Million USD | -1269.3% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -70.945% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -5355.094% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -546.811% |
| Arcellx, Inc. | 825.13 Million USD | 52.241% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -382.717% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 14.753% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1181.548% |
| Moolec Science SA | 24.05 Million USD | -1538.482% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -27.07% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -287.451% |
| Royalty Pharma plc | 16.38 Billion USD | 97.594% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 33.765% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -5533.83% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -3176.508% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -74.324% |
| Humacyte, Inc. | 128.22 Million USD | -207.336% |
| Structure Therapeutics Inc. | 482.01 Million USD | 18.244% |
| 89bio, Inc. | 596.26 Million USD | 33.91% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -56.285% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -21201.405% |
| Genelux Corporation | 27.89 Million USD | -1312.813% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -340.786% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -71.764% |
| Notable Labs, Ltd. | 19.54 Million USD | -1916.662% |
| Liquidia Corporation | 120.43 Million USD | -227.221% |
| Mustang Bio, Inc. | 17.74 Million USD | -2121.148% |
| Immunovant, Inc. | 666.71 Million USD | 40.893% |
| Quantum-Si incorporated | 298.25 Million USD | -32.129% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -172.904% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -627.614% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -124.486% |
| Acasti Pharma Inc. | 73.3 Million USD | -437.621% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -8556.671% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1408.895% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 59.155% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -7493.106% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -1629.845% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -663.669% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -118.094% |
| PepGen Inc. | 143.05 Million USD | -175.477% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -931.154% |
| United Therapeutics Corporation | 7.16 Billion USD | 94.502% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -1954.084% |
| Solid Biosciences Inc. | 164.93 Million USD | -138.922% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -6610.805% |
| Immuneering Corporation | 102.58 Million USD | -284.148% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -9046.223% |
| Silo Pharma, Inc. | 7.74 Million USD | -4987.385% |
| Belite Bio, Inc | 94.64 Million USD | -316.386% |
| XOMA Corporation | 234.3 Million USD | -68.192% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -68.995% |
| Bionomics Limited | 27.64 Million USD | -1325.276% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 1.826% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -266.965% |
| uniQure N.V. | 831.68 Million USD | 52.617% |
| Cassava Sciences, Inc. | 151.66 Million USD | -159.837% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -8747.312% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -43.884% |
| Forte Biosciences, Inc. | 38.98 Million USD | -910.97% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -9575.055% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -969.957% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -5355.094% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -11117.649% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -3233.694% |
| Altimmune, Inc. | 210.64 Million USD | -87.085% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 49.34% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -266.965% |
| Compugen Ltd. | 121.33 Million USD | -224.786% |
| Peak Bio, Inc. | 2.59 Million USD | -15077.697% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -128.679% |
| Benitec Biopharma Inc. | 52.21 Million USD | -654.79% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -15.274% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1033.282% |
| Zura Bio Limited | 100.84 Million USD | -290.782% |
| PolyPid Ltd. | 15.37 Million USD | -2463.596% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -230.362% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1033.282% |
| Instil Bio, Inc. | 325.63 Million USD | -21.02% |
| argenx SE | 4.54 Billion USD | 91.325% |
| Immunome, Inc. | 148.54 Million USD | -165.3% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -151.204% |
| Verona Pharma plc | 308.12 Million USD | -27.895% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -353.174% |
| Shattuck Labs, Inc. | 159.56 Million USD | -146.97% |
| CervoMed Inc. | 9.97 Million USD | -3851.619% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -109.108% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -3360.45% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -119.657% |
| Moolec Science SA | 24.05 Million USD | -1538.482% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -6341.803% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -127.863% |
| AnaptysBio, Inc. | 452.38 Million USD | 12.89% |
| Design Therapeutics, Inc. | 289.64 Million USD | -36.056% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -441.127% |
| NeurAxis, Inc. | 509.49 Thousand USD | -77245.937% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -7173.459% |
| Lumos Pharma, Inc. | 40.63 Million USD | -869.723% |
| Achilles Therapeutics plc | 161.45 Million USD | -144.076% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -353.174% |
| 180 Life Sciences Corp. | 5.25 Million USD | -7392.686% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -459.546% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -4503.364% |
| Nutriband Inc. | 7.51 Million USD | -5142.356% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -54.73% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -97.729% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -417.079% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -580.427% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 25.157% |
| Palisade Bio, Inc. | 14.05 Million USD | -2704.412% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -87.392% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 73.003% |
| Neurogene Inc. | 222.57 Million USD | -77.055% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 39.056% |
| AEON Biopharma, Inc. | 6.84 Million USD | -5657.137% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 13.014% |
| Sesen Bio, Inc. | 189.17 Million USD | -108.314% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -44.952% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -2773.977% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 49.5% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -47.597% |
| Athira Pharma, Inc. | 160.24 Million USD | -145.921% |
| Vaccinex, Inc. | 3.63 Million USD | -10753.098% |
| HCW Biologics Inc. | 28.51 Million USD | -1282.06% |
| XOMA Corporation | 234.3 Million USD | -68.192% |
| Nektar Therapeutics | 398.03 Million USD | 0.994% |
| Arvinas, Inc. | 1.3 Billion USD | 69.793% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2213.015% |
| Merus N.V. | 458.49 Million USD | 14.05% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -92.829% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -118.683% |
| Rezolute, Inc. | 132.73 Million USD | -196.885% |
| Clene Inc. | 52.34 Million USD | -652.901% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -2540.574% |
| BeyondSpring Inc. | 24.8 Million USD | -1488.504% |
| Synlogic, Inc. | 75.55 Million USD | -421.61% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -3222.172% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -4108.415% |
| Peak Bio, Inc. | 2.59 Million USD | -15077.697% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -125.401% |
| Krystal Biotech, Inc. | 818.35 Million USD | 51.845% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -63.899% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 45.704% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -10916.406% |
| MannKind Corporation | 475.19 Million USD | 17.071% |
| Ikena Oncology, Inc. | 192.09 Million USD | -105.15% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -2846.583% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -238.149% |
| Gossamer Bio, Inc. | 311.91 Million USD | -26.34% |
| CohBar, Inc. | 16.36 Million USD | -2307.943% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1020.712% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -5287.232% |
| Legend Biotech Corporation | 1.84 Billion USD | 78.683% |
| Mural Oncology plc | 301.74 Million USD | -30.599% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1162.457% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -6837.463% |
| Disc Medicine, Inc. | 367.99 Million USD | -7.087% |
| Champions Oncology, Inc. | 26.13 Million USD | -1408.021% |
| REGENXBIO Inc. | 573.97 Million USD | 31.342% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -14451.833% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -155.254% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -3163.413% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -15.893% |
| Vaxart, Inc. | 91.83 Million USD | -329.136% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -557.847% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -165.681% |
| Cellectis S.A. | 334.27 Million USD | -17.892% |
| Longeveron Inc. | 12.17 Million USD | -3135.966% |
| Repare Therapeutics Inc. | 253.9 Million USD | -55.209% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 87.929% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -96.207% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 81.132% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -24150.831% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -41.901% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -141.619% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -184.031% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1444.064% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.266% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 65.849% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3126.796% |
| Veru Inc. | 50.59 Million USD | -678.869% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -765.093% |
| Cingulate Inc. | 3.49 Million USD | -11186.932% |
| Passage Bio, Inc. | 150.54 Million USD | -161.766% |
| Context Therapeutics Inc. | 16.06 Million USD | -2353.356% |
| Exicure, Inc. | 11.58 Million USD | -3303.074% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -4.794% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -143.796% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -2155.472% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -18.432% |
| Nuvalent, Inc. | 732.38 Million USD | 46.193% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -2537.004% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -340.043% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -2676.943% |
| OmniAb, Inc. | 401.98 Million USD | 1.967% |
| Anew Medical, Inc. | 19.45 Million USD | -1925.478% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1374.474% |
| Lipocine Inc. | 23 Million USD | -1613.294% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -181.871% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -28.966% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -369.466% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -224.236% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -4866.301% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 55.334% |
| Ocugen, Inc. | 64.54 Million USD | -510.526% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -216.423% |
| Q32 Bio Inc. | 306.11 Million USD | -28.733% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -9264.924% |
| Alumis Inc. Common Stock | 89.61 Million USD | -339.758% |
| Equillium, Inc. | 50.53 Million USD | -679.885% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -424.072% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -854.791% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -23069.316% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1407.502% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -511.53% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -10473.224% |
| Dominari Holdings Inc. | 57.55 Million USD | -584.659% |
| Edesa Biotech, Inc. | 8.89 Million USD | -4332.583% |
| vTv Therapeutics Inc. | 11.01 Million USD | -3476.656% |
| Bio-Techne Corporation | 2.81 Billion USD | 85.992% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 57.948% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 51.435% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -41.925% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -844.981% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 40.97% |
| Nkarta, Inc. | 378.88 Million USD | -4.009% |
| BioCardia, Inc. | 2.98 Million USD | -13093.036% |
| Iterum Therapeutics plc | 26.25 Million USD | -1400.727% |